Pharmaceutical industry in China

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada

Retrieved on: 
Monday, July 12, 2021

TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (medac) to commercialize treosulfan, a bifunctional alkylating agent, in Canada.

Key Points: 
  • TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (medac) to commercialize treosulfan, a bifunctional alkylating agent, in Canada.
  • Michael Pine, Senior Vice President of Business Development and Strategy, commented, We are pleased to have signed our third licensing agreement with medac and to expand our strong collaboration.
  • medac GmbH is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business.
  • Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy.

Neurana Pharmaceuticals to Participate at William Blair Biotech Conference

Retrieved on: 
Monday, July 12, 2021

SAN DIEGO, July 12, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced participation at the William Blair Biotech Focus Conference.

Key Points: 
  • SAN DIEGO, July 12, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced participation at the William Blair Biotech Focus Conference.
  • The conference takes place virtually July 14-15th.
  • Presentations will be available for registered attendees via the William Blair conference site.
  • Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back.

Acerus Provides Update on Litigation with Recipharm

Retrieved on: 
Monday, July 12, 2021

TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (Recipharm) alleged that Acerus claim for damages was barred by the terms of the companies manufacturing contract.

Key Points: 
  • TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (Recipharm) alleged that Acerus claim for damages was barred by the terms of the companies manufacturing contract.
  • "This is an important step forward in Acerus effort to hold Recipharm accountable for its contractual breaches, said Ed Gudaitis, President and Chief Executive Officer of Acerus.
  • Manufacturers in the pharmaceutical industry rely on contract manufacturing organizations like Recipharm to ensure that patients have access to the medicines they need.
  • On June 18, 2020, Acerus announced it had commenced litigation against Recipharm, a wholly-owned subsidiary of Recipharm AB, in the Commercial Court of London.

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

Retrieved on: 
Monday, July 12, 2021

Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs.

Key Points: 
  • Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs.
  • Dr. Costas previous roles include positions of increasing responsibility in clinical development at Merck, Celgene, Novartis and most recently as Chief Medical Officer at Rafael Pharmaceuticals.
  • We are excited to welcome Octvio, especially as our lead program enters late-stage clinical studies, said Chandler Robinson, MD, Chief Executive Officer of Monopar.
  • I am thrilled to be joining this accomplished management team, as Monopars Chief Medical Officer, said Dr. Costa.

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

Retrieved on: 
Monday, July 12, 2021

ALPHARETTA, Ga., July 12, 2021 /PRNewswire/ --Avanos Medical, Inc. (NYSE: AVNS) today announced that Moji James has been appointed senior vice president & general counsel.

Key Points: 
  • ALPHARETTA, Ga., July 12, 2021 /PRNewswire/ --Avanos Medical, Inc. (NYSE: AVNS) today announced that Moji James has been appointed senior vice president & general counsel.
  • In this role, James will oversee the Company's legal, government relations and global security functions.
  • During her more than 25 years practicing law, James has supported the development and commercialization of innovative drugs, biologics and vaccines.
  • Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer).

Global Animal Pharmaceuticals (Drugs, Vaccine, Medicated Feed) Market, Forecast & Opportunities, 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021

The "Global Animal Pharmaceuticals Market, By Product Type (Drugs, Vaccine, Medicated Feed), By Animal Type, By Route of Administration, By Type of Infection, By End User, By Distribution Channel, By Region, By Company, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Animal Pharmaceuticals Market, By Product Type (Drugs, Vaccine, Medicated Feed), By Animal Type, By Route of Administration, By Type of Infection, By End User, By Distribution Channel, By Region, By Company, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • Animal pharmaceuticals are highly beneficial in the diagnosis and treatment of animal disorders.
  • The emergence of new economies has led more governments and pharma companies to fund animal healthcare, consequently pushing the market forward.
  • The Global Animal Pharmaceuticals market is segmented based on product type, animal type, route of administration, type of infection, end-user, distribution channel and region.

FFF Enterprises Celebrates 33 Years of Helping Healthcare Care®

Retrieved on: 
Thursday, July 8, 2021

FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.

Key Points: 
  • FFF Enterprises business models and innovations continue to evolve to ensure the safety and efficacy of the biopharmaceuticals marketplace.
  • With more than 33 years of experience in product allocation management, FFF Enterprises is dedicated to meeting the needs of our most precious patients.
  • Everything we do affirms our dedication to sustain a reliable, secure pharmaceutical supply chain in the pursuit of our mission of Helping Healthcare Care.
  • Please visit FFF Enterprises' news site , as well as LinkedIn , Instagram , Facebook and YouTube for more information about the company.

Moderna Vice President of US Manufacturing to Deliver Keynote Address at the 2021 ISPE Facilities of the Future Conference

Retrieved on: 
Thursday, July 8, 2021

Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.

Key Points: 
  • Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality.
  • Before Moderna, he was with Alexion Pharmaceuticals serving as Vice President of Quality Assurance and Quality Control.
  • The opening keynote session COVID's Impact on Pharma Facilities of the Future will take a high-level look ahead at global pharmaceutical manufacturing and related regulatory systems.
  • Nickerson will discuss the impact of COVID on the industry and the applications of future manufacturing operations.

Nippon Express (India) Newly Acquires GDP Certification at Three Locations

Retrieved on: 
Thursday, July 8, 2021

With the manufacturers of generics and other pharmaceuticals enjoying steady growth, India's pharmaceutical industry has rolled out countless products for the domestic market and rapidly expanded its exports.

Key Points: 
  • With the manufacturers of generics and other pharmaceuticals enjoying steady growth, India's pharmaceutical industry has rolled out countless products for the domestic market and rapidly expanded its exports.
  • In 2019, NE India acquired GDP certification for a temperature-controlled hub in Hyderabad handling international air cargo and, having newly obtained GDP certification for temperature-controlled hubs in Delhi, Mumbai, and Ahmedabad, it can now more extensively provide the safety and thorough quality control required for pharmaceutical transport.
  • Moving forward, the company will continue expanding its pharmaceutical transport network in other regions hosting pharmaceutical plants.
  • Nippon Express remains committed to enhancing its services to meet increasingly sophisticated and diverse pharmaceutical logistics needs and to strengthening its efforts on behalf of the pharmaceutical industry, identified as a priority industry in the company's business plan.

Biofrontera reports preliminary revenue for the month of June 2021

Retrieved on: 
Tuesday, July 6, 2021

The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.

Key Points: 
  • The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.
  • Ameluz has been marketed in the EU since 2012 and in the United States since May 2016.
  • In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.
  • Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house.